Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450

被引：22

作者：

Yang, Ruirui ^{[1
]}

Luo, Zhiqiang ^{[1
]}

Liu, Yang ^{[1
]}

Sun, Mohan ^{[1
]}

Zheng, Ling ^{[1
]}

Chen, Yingying ^{[1
]}

Li, Yanping ^{[1
]}

Wang, Hao ^{[1
]}

Chen, Lingzhu ^{[1
]}

Wu, Ming ^{[1
]}

Zhao, Huihui ^{[2
]}

机构：

[1] Beijing Univ Chinese Med, Sch Chinese Mat Med, 6 Zhonghuan South Rd, Beijing 100102, Peoples R China

[2] Beijing Univ Chinese Med, Sci & Technol Dept, 11 North Third Ring Rd, Beijing 100029, Peoples R China

来源：

CURRENT DRUG METABOLISM | 2016年 / 17卷 / 07期

基金：

中国国家自然科学基金;

关键词：

Angiotensin receptor blockers (ARBs); clinical relevance; CYP450; enzymes; hypertension; mechanisms; pharmacokinetic interactions; CARBOXYLIC-ACID METABOLITE; DIRECT RENIN INHIBITOR; CANDESARTAN CILEXETIL; PHARMACOKINETIC INTERACTIONS; AZILSARTAN MEDOXOMIL; ABSOLUTE BIOAVAILABILITY; ANTIHYPERTENSIVE AGENTS; ORAL BIOAVAILABILITY; DOSE COMBINATIONS; BLOOD-PRESSURE;

D O I：

10.2174/1389200217666160524143843

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Angiotensin receptor blockers (ARBs) are the most recent class of agents for the treatment of hypertension. However, ARBs may cause a low incidence of headache, upper respiratory infection, back pain, muscle cramps, fatigue, dizziness, and many other side effects. In some cases, such toxicity is associated with pharmacokinetic alterations. Methods: The cytochrome P450 (CYP) enzyme system plays an important role in a lot of clinically important pharmacokinetic drug interactions. To identify relevant studies on drug-drug and food-drug pharmacokinetic interactions with the ARBs, a literature search of Google Scholar was performed from January 1994 to June 2015, with the following keywords: 'losartan', 'valsartan,' 'candesartan,' 'irbesartan,' 'telmisartan,' 'eprosartan,' 'olmesartan,' and 'azilsartan', combined with the keyword 'pharmacokinetic interactions' and 'CYP'. Results: Based on the literatures published, it has been demonstrated that pharmacokinetic interactions of losartan with other agents are mainly via CYP2C9- and CYP3A4-mediated, the role played by CYP enzyme system in the metabolism of valsartan, candesartan, irbesartan, and azilsartan appears modest, and cytochrome P450 system has no influence on the metabolism of telmisartan, eprosartan, olmesartan. Therefore, according to these pharmacokinetic findings, no dosage adjustment is recommended when eprosartan, telmisartan and olmesartan are combined with other pharmacological agents in patients with hypertension. Conclusion: This review summarize the available data on cytochrome P450 - related drug-drug interactions reported in the literature for the eight ARBs. Knowledge of the pharmacokinetic properties of the ARBs should allow the avoidance of the majority of drug interactions without compromising therapeutic benefits.

引用

页码：681 / 691

页数：11

共 115 条

[61] Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus [J].